The landscape of mental health treatment and addiction medicine is undergoing a seismic shift. As traditional pharmacological approaches face criticism for their limited efficacy and potential for long-term dependency, researchers and clinicians are increasingly turning their gaze toward ethnobotanical compounds. Among these, ibogaine research has moved from the fringes of alternative medicine to the forefront […]
As we navigate the second half of 2026, the scientific landscape surrounding psilocybin has reached a pivotal inflection point. Once confined to the shadows, psilocybin is now at the forefront of neurological research, with landmark studies emerging from institutions like the Karolinska Institutet and McGill University. From the United States to Europe and beyond, clinical […]
3,4-Methylenedioxymethamphetamine (MDMA), widely known as ecstasy or molly, occupies a unique and controversial space in both recreational culture and modern clinical science. Since its initial synthesis in 1914, MDMA has evolved from a laboratory curiosity into a globally recognized psychoactive compound. In 2026, the discourse surrounding MDMA is shifting, moving beyond its historical stigma toward […]
The scientific investigation of ibogaine as a potential intervention for addiction has evolved from anecdotal reports and observational studies to more rigorous clinical research over the past three decades. While the compound remains in a complex regulatory position across much of the world, preventing large-scale randomized controlled trials in many jurisdictions, a growing body of […]